Working… Menu

A Phase I/II Study of GX15-070MS in Untreated CLL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00600964
Recruitment Status : Completed
First Posted : January 25, 2008
Last Update Posted : May 12, 2014
Information provided by:
Teva Pharmaceutical Industries

Brief Summary:
This protocol is being run to determine the best phase II dose and schedule of obatoclax in patients with previously untreated CLL.

Condition or disease Intervention/treatment Phase
Chronic Lymphocytic Leukemia Drug: GX15-070MS Phase 1

Detailed Description:
Both 1 hour and 3 hour infusions of obatoclax every 3 weeks will be evaluated in ascending doses.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center, Open-Label, Phase I/II Study of Single-Agent GX15-070MS Administered Every 2 to 3 Weeks to Patients With Previously-Treated Chronic Lymphocytic Leukemia (CLL)
Study Start Date : September 2004
Actual Primary Completion Date : January 2006
Actual Study Completion Date : January 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leukemia

Arm Intervention/treatment
Experimental: GX15-070MS
GX15-070MS at various doses and schedules
Drug: GX15-070MS
A 60-minute or 3-hour IV infusion every 2-3 weeks.
Other Name: Obatoclax

Drug: GX15-070MS
GX15-070MS at various doses and schedules
Other Name: Obatoclax

Primary Outcome Measures :
  1. Determine the recommended Phase II dose of GX15-070MS administered as a 60-minute and/or 3-hour infusion every 2 to 3 weeks [ Time Frame: 14 days ]

Secondary Outcome Measures :
  1. Estimate the response rate of previously-treated patients with CLL at the recommended Phase II dose of GX15-070MS administered as a 60-minute and/or 3-hour infusion every 2 to 3 weeks. [ Time Frame: 14 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed B-CLL
  • Previous standard systemic chemotherapy, including fludarabine. There are no limitations on additional, allowable type and amount of prior therapy. Acute toxicities from prior therapy must have resolved to ≤Grade 1
  • Age ≥18 years
  • ECOG Performance Status ≤1
  • Life expectancy of >8 weeks

Exclusion Criteria:

  • Patients receiving any other investigational agents (e.g., under another IND) or commercial agents or therapies administered with the intent to treat their malignancy
  • Patients with history of seizure disorders
  • Pregnant women and women who are breast feeding
  • HIV-positive patients receiving combination anti-retroviral therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00600964

Layout table for location information
United States, California
University of CA- San Diego
La Jolla, California, United States, 92093
United States, District of Columbia
Lombardi Cancer Center
Washington, District of Columbia, United States, 20007
United States, Pennsylvania
Milton S Hershey Medical Center Penn State Cancer Institute
Hershey, Pennsylvania, United States, 17033
United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Canada, Ontario
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
Gemin X
Layout table for investigator information
Study Director: Jean Viallet, MD Gemin X, Inc.
Publications of Results:
Layout table for additonal information
Responsible Party: Jean Viallet, MD, Gemin X, Inc. Identifier: NCT00600964    
Other Study ID Numbers: GX004
First Posted: January 25, 2008    Key Record Dates
Last Update Posted: May 12, 2014
Last Verified: May 2014
Keywords provided by Teva Pharmaceutical Industries:
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action